Silencing of microRNAs in vivo with ‘antagomirs’ View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-10-30

AUTHORS

Jan Krützfeldt, Nikolaus Rajewsky, Ravi Braich, Kallanthottathil G. Rajeev, Thomas Tuschl, Muthiah Manoharan, Markus Stoffel

ABSTRACT

miRNAs acting naturallyThe discovery of microRNAs (miRNAs), the non-coding RNAs thought to be involved in many biological processes, is changing our perception of gene regulation. Little is known about their function in mammalian systems in vivo, but a newly developed group of compounds that silences miRNAs in mice should provide a powerful tool for the study of their function — and a potential therapeutic strategy for silencing miRNAs in disease. These ‘antagomirs’ are chemically engineered oligonucleotides with sequences that complement natural miRNAs. Intravenous administration of antagomirs to miR-16, -122, -192 and -194 in mice caused a marked reduction of corresponding miRNA expression in liver, lung, kidney, heart, muscle, intestine, fat, skin, bone marrow, ovaries and adrenals. In worms and flies, miRNAs play important developmental roles in the embryo. In vertebrates, various developmental genes have been shown to be targets of miRNA regulation, but there were no examples of miRNAs playing specific roles in known developmental processes. Now one such example has been found: miR-196 acts in mouse embryos as a mechanism to ensure accurate expression of genes primarily regulated by Hoxb8 and Shh transcription factors. This supports the idea that vertebrate miRNAs may function as a secondary level of gene regulation. More... »

PAGES

685-689

Journal

TITLE

Nature

ISSUE

7068

VOLUME

438

Related Patents

  • Micro-Rna-Based Methods And Compositions For The Diagnosis And Treatment Of Colon Related Diseases
  • Methods And Compositions For The Treatment Of Eye Disorders With Increased Intraocular Pressure
  • Multimeric Oligonucleotides Compounds Having Cleavable Linkers
  • Nucleic Acid Functionalized Nanoparticles For Therapeutic Applications
  • Mir-106a For Diagnosing Poor Survival Prognosis Colon Adenocarcinoma.
  • Sequence-Specific Cellular Uptake Of Spherical Nucleic Acid Nanoparticle Conjugates
  • Methods And Compositions For The Treatment Of Eye Disorders With Increased Intraocular Pressure
  • Modified Antimir-138 Oligonucleotides
  • Compositions And Methods For Modulating Atp2a2 Expression
  • Chiral Nucleic Acid Adjuvant Having Anti-Allergic Activity, And Anti-Allergic Agent
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Nucleic Acid Functionalized Nonoparticles For Therapeutic Applications
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Raav-Based Compositions And Methods
  • Aav-Based Treatment Of Cholesterol-Related Disorders
  • Oligonucleotides Useful For Detecting And Analyzing Nucleic Acids Of Interest
  • Double-Stranded Agents For Delivering Therapeutic Oligonucleotides
  • Methods And Compositions For The Treatment Of Eye Disorders With Increased Intraocular Pressure
  • 5′-End Derivatives
  • Method For Promoting Angiogenesis, Vascularization Or Vessel Repair Or For Inhibiting Tumor Angiogenesis
  • Compositions And Methods For Modulating Utrn Expression
  • Raav-Based Compositions And Methods For Treating Amyotrophic Lateral Sclerosis
  • Microrna Inhibitors
  • Supercharged Proteins For Cell Penetration
  • Method For Treating Myocardial Infarct
  • Using Modulator Of Tumor Necrosis Factor (Tnf) Pathway Such As Infliximab, Simvastatin; Drug Screening
  • Polycomb-Associated Non-Coding Rnas
  • Antisense Microrna And Uses Therefor
  • Mir-122* As An Active Micro-Rna, Compositions Comprising The Same And Uses Thereof
  • Micrornas In Neurodegenerative Disorders
  • Methods For Regulating Neural Differentiation
  • Method For The Synthesis Of Phosphorus Atom Modified Nucleic Acids
  • Compositions And Methods For The Diagnosis And Treatment Of Bone Fractures And Disorders
  • Multimeric Oligonucleotides Compounds
  • Corneal Administration; Rna Interference; Glaucoma, Diabetic Retinopathy
  • Gene Vector
  • Sirna And Their Use In Methods And Compositions For The Treatment And / Or Prevention Of Eye Conditions
  • Compositions And Methods For Modulating Smn Gene Family Expression
  • The Use Of Mirna Particles And Mirna Antagomir For Diagnostics, Prevention And Treatment Of Multiple Sclerosis
  • Method Of Inhibiting Mir-33 Using A Modified Oligonucleotide
  • Microrna (Mirna) And Downstream Targets For Diagnostic And Therapeutic Purposes
  • Chiral Nucleic Acid Adjuvant
  • Targeting Micrornas For The Treatment Of Fibrosis
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Mir-92 Inhibitors And Uses Thereof
  • Aav Treatment Of Huntington's Disease
  • Micro-Rna-Based Methods And Compositions For The Diagnosis And Treatment Of Colon Related Diseases
  • Modulation Of Innate Immunity Receptors' Signaling By Micrornas Mir-146a And Mir-146b
  • Esophageal Microrna Expression Profiles In Eosinophilic Esophagitis
  • Reduced Size Self-Delivering Rnai Compounds
  • Polycomb-Associated Non-Coding Rnas
  • Aav's And Uses Thereof
  • Compositions And Methods For Modifying A Predetermined Target Nucleic Acid Sequence
  • Combination Treatment For The Treatment Of Hepatitis C Virus Infection
  • Methods And Compositions For Detection Of Cowden Syndrome (Cs) And Cs-Like Syndrome
  • Methods For Promoting Angiogenesis, Vascularisation Or Vessel Repair Or For Inhibiting Tumour Angiogenesis
  • Sirna And Their Use In Methods And Compositions For The Treatment And/Or Prevention Of Eye Conditions
  • Recombinant Aavs Having Useful Transcytosis Properties
  • Micrornas
  • Mir-21 For Diagnosing Poor Survival Prognosis Colon Adenocarcinoma
  • Modified Aav Constructs And Uses Thereof
  • Administration Of Exogenous Mirna Or Sirna
  • Heterologous Targeting Peptide Grafted Aavs
  • Double-Stranded Agents For Delivering Therapeutic Oligonucleotides
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Inhibitors Of The Microrna Argonaute Protein Complex
  • Regulation Of Hematopoietic Stem Cell Functions Through Micrornas
  • Treatment Of Cns Conditions
  • Oligonucleotide Conjugates
  • Templated Nanoconjugates
  • Microrna Expression Profile Associated With Pancreatic Cancer
  • Poly Oligomer Compound With Biocleavable Conjugates
  • Polycomb-Associated Non-Coding Rnas
  • Isolation Of Novel Aav's And Uses Thereof
  • Microrna-24
  • Heterologous Targeting Peptide Grafted Aavs
  • Microrna Composition For The Treatment Of Neuroblastoma
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Microrna Expression Profile Associated With Pancreatic Cancer
  • Nucleic Acid Functionalized Nanoparticles For Therapeutic Applications
  • Mirna Compounds For Treatment Of Prostate Carcinoma
  • Raav-Based Compositions And Methods For Treating Alpha-1 Anti-Trypsin Deficiencies
  • Cell Penetrating Peptides
  • Raav-Based Compositions And Methods For Treating Alpha-1 Anti-Trypsin Deficiencies
  • Targeting Micrornas For The Treatment Of Fibrosis
  • Microrna-Based Methods And Assays For Osteocarcinoma
  • Antisense Oligonucleotides For Inhibition Of Microrna-21
  • Microrna-Based Methods And Compositions For The Diagnosis, Prognosis And Treatment Of Tumor Involving Chromosomal Rearrangements
  • Hybrid Oligonucleotides And Uses Thereof
  • Aav's And Uses Thereof
  • Novel Micrornas For The Detection And Isolaton Of Human Embryonic Stem Cell-Derived Cardiac Cell Types
  • Cell-Penetrating Peptides Having A Central Hydrophobic Domain
  • Targets For Use In Diagnosis, Prognosis And Therapy Of Cancer
  • Corneal Administration; Rna Interference; Glaucoma, Diabetic Retinopathy
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Compositions And Methods For Modulating Hemoglobin Gene Family Expression
  • Mir-29a For Diagnosing Poor Survival Prognosis Colon Adenocarcinoma.
  • Compositions And Methods For Enhancing Oil Content In Plants
  • Delivery Of Oligonucleotide Functionalized Nanoparticles
  • Receptor-Mediated Delivery: Compositions And Methods
  • Targeting Micrornas For The Treatment Of Fibrosis
  • Microrna Expression Profile Associated With Pancreatic Cancer
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Nucleic Acid Functionalized Nanoparticles For Therapeutic Applications
  • Microrna-Based Methods And Assays For Osteocarcinoma
  • Antisense Oligonucleotides For Inhibition Of Microrna-21
  • Templated Nanoconjugates
  • Polycomb-Associated Non-Coding Rnas
  • Aav-Based Treatment Of Cholesterol-Related Disorders
  • Microrna (Mirna) And Downstream Targets For Diagnostic And Therapeutic Purposes
  • Recombinant Aavs Having Useful Transcytosis Properties
  • Aav's And Uses Thereof
  • Compositions And Methods For Modifying A Predetermined Target Nucleic Acid Sequence
  • Combination Treatment For The Treatment Of Hepatitis C Virus Infection
  • Inhibition Of Microrna-134 For The Treatment Of Seizure-Related Disorders And Neurologic Injuries
  • Poly Oligomer Compound With Biocleavable Conjugates
  • Isolation Of Novel Aav's And Uses Thereof
  • Microrna Expression Profile Associated With Pancreatic Cancer
  • Micro-Rna's That Regulate Muscle Cells
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Muc1 And Galectin-3
  • Microrna (Mirna) And Downstream Targets For Diagnostic And Therapeutic Purposes
  • Microrna Inhibitors
  • Chiral Control
  • Protein Surface Remodeling
  • Polycomb-Associated Non-Coding Rnas
  • Sirnas And Their Use In Methods And Compositions For The Treatment And/Or Prevention Of Eye Conditions
  • Aav's And Uses Thereof
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Methods And Compositions For The Treatment Of Intestinal Conditions
  • Nanoconjugates Able To Cross The Blood-Brain Barrier
  • Modulation Of T Cell Signaling Threshold And T Cell Sensitivity To Antigens
  • Methods For Inducing Cardiomyocyte Proliferation
  • Modulators Of Mir-323-3p For The Prevention Or Treatment Of Rheumatoid Arthritis
  • Isolation Of Novel Aav's And Uses Thereof
  • Targets For Use In Diagnosis, Prognosis And Therapy Of Cancer
  • Microrna (Mirna) And Downstream Targets For Diagnostic And Therapeutic Purposes
  • Methods And Compositions For Reducing Viral Genome Amounts In A Target Cell
  • Polyvalent Rna-Nanoparticle Compositions
  • Raav-Based Compositions And Methods For Treating Amyotrophic Lateral Sclerosis
  • Methods And Compositions For Reducing Viral Genome Amounts In A Target Cell
  • Corneal Administration; Rna Interference; Glaucoma, Diabetic Retinopathy
  • Recombinant Aavs Having Useful Transcytosis Properties
  • Targeting Glioma Stem Cells By Sequence-Specific Functional Inhibition Of Pro-Survival Oncomir-138
  • The Mirna-212/132 Family As A Therapeutic Target
  • Microrna (Mirna) And Down-Stream Targets For Diagnostic And Therapeutic Purposes
  • Methods Employing Non-Coding Rna Expression Assays
  • Sequence-Specific Inhibition Of Small Rna Function
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Chiral Nucleic Acid Adjuvant Having Immunity Induction Activity, And Immunity Induction Activator
  • Microrna Inhibitors Comprising Locked Nucleotides
  • Antisense Microrna And Uses Therefor
  • Method For The Synthesis Of Phosphorus Atom Modified Nucleic Acids
  • Asymmetric Auxiliary Group
  • Raav-Based Compositions And Methods
  • Antisense Rna For Treating Cancer And Inhibition Of Metastasis And Vectors For Antisense Sequestration
  • Magnetic Nanoparticle-Samirna Complex And Method For Preparing Same
  • Cns Targeting Aav Vectors And Methods Of Use Thereof
  • Uses And Compositions Comprising Mirnas
  • Method For The Inhibition Of Angiogenesis
  • Microrna Expression Profile Associated With Pancreatic Cancer
  • Use Of Nucleic Acids With Reduced Pressure Therapy
  • Micro-Rna-Based Methods And Compositions For The Diagnosis And Treatment Of Colon Related Diseases
  • Methods For The Synthesis Of Functionalized Nucleic Acids
  • Mir-203 For Diagnosing Poor Survival Prognosis Colon Adenocarcinoma.
  • Chiral Design
  • Compounds Of Chemically Modified Oligonucleotides And Methods Of Use Thereof
  • Medicament For The Treatment Of Cardiac Disease
  • Micro-Rna Mediated Modulation Of Colony Stimulating Factors
  • Distinguishing Benign And Malignant Indeterminate Thyroid Lesions
  • Anti-Mir-27b And Anti-Mir-148a Oligonucleotides As Therapeutic Tools For Treating Dyslipidemias And Cardiovascular Diseases
  • Identification Of Novel Genes Coding For Small Temporal Rnas
  • Isolation Of Novel Aav's And Uses Thereof
  • Methods And Compositions For The Diagnosis And Treatment Of Esphageal Adenocarcinomas
  • Methods For Regulating Neural Differentiation
  • Methods For Use In Modulating Mir-122a
  • Microrna (Mirna) For The Diagnosis And Treatment Of Heart Diseases
  • Pharmaceutical Compositions For Treatment Of Microrna Related Diseases
  • Transcriptome-Wide Design Of Selective, Bioactive Small Molecules Targetting Rna
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Methods And Compositions For The Treatment Of Eye Disorders With Increased Intraocular Pressure
  • Modulation Of 11beta-Hydroxysteriod Dehydrogenase 1 Expression For The Treatment Of Ocular Diseases
  • Modulating Immune System Development And Function Through Microrna Mir-146
  • Compositions And Methods For Modulating Smn Gene Family Expression
  • Aav Treatment Of Huntington's Disease
  • Multicistronic Expression Constructs
  • Raav-Based Compositions And Methods For Treating Amyotrophic Lateral Sclerosis
  • Method For Promoting Angiogenesis, Vascularization Or Vessel Repair
  • Reduced Size Self-Delivering Rnai Compounds
  • Methods Employing Non-Coding Rna Expression Assays
  • Polycomb-Associated Non-Coding Rnas
  • Methods Of Delivering Multiple Targeting Oligonucleotides To A Cell Using Cleavable Linkers
  • Methods And Compositions For The Detection And Treatment Of Cancer Involving Mirnas And Mirna Inhibitors And Targets
  • Chiral Auxiliaries
  • Cns Targeting Aav Vectors And Methods Of Use Thereof
  • Mir-92 Inhibitors And Uses Thereof
  • Use Of Mir-199a-5p, Targets And/Or Inhibitors Thereof For The Diagnosis, Prognosis And Treatment Of Fibroproliferative Disorders
  • Modulation Of T Cell Signaling Threshold And T Cell Sensitivity To Antigens
  • Targets For Use In Diagnosis, Prognosis And Therapy Of Breast Cancer
  • Gene Vector
  • The Mirna-212/132 Family As A Therapeutic Target
  • Chiral Control
  • Gene Vector
  • Raav-Based Compositions And Methods For Treating Amyotrophic Lateral Sclerosis
  • Corneal Administration; Rna Interference; Glaucoma, Diabetic Retinopathy
  • Methods Of Delivering Multiple Targeting Oligonucleotides To A Cell Using Cleavable Linkers
  • Light Inducible Antisense Oligonucleotides For In Vivo Application
  • Methods And Compositions For The Detection And Treatment Of Cancer Involving Mirnas And Mirna Inhibitors And Targets
  • Reduced Size Self-Delivering Rnai Compounds
  • Methods Employing Non-Coding Rna Expression Assays
  • Polyvalent Rna-Nanoparticle Compositions
  • Aav Treatment Of Huntington's Disease
  • Multicistronic Expression Constructs
  • Method For Promoting Angiogenesis, Vascularization Or Vessel Repair
  • Micro-Rna-Based Methods And Compositions For The Diagnosis And Treatment Of Colon Related Diseases
  • Method For Promoting Angiogenesis, Vascularisation Or Vessel Repair Or For Inhibiting Tumour Angiogenesis
  • Micromirs
  • Polycomb-Associated Non-Coding Rnas
  • Multimeric Oligonucleotide Compounds Having Non-Nucleotide Based Cleavable Linkers
  • Protein Surface Remodeling
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Method For Modulating The Function, Growth Or Differentiation Of A Cell
  • Compositions And Methods For Cancer Diagnosis And Treatment
  • Chiral Auxiliaries
  • Corneal Administration; Rna Interference; Glaucoma, Diabetic Retinopathy
  • Mir-92 Inhibitors And Uses Thereof
  • Use Of Mir-199a-5p, Targets And/Or Inhibitors Thereof For The Diagnosis, Prognosis And Treatment Of Fibroproliferative Disorders
  • Microrna-Based Methods And Assays For Osteocarcinoma
  • Polycomb-Associated Non-Coding Rnas
  • Modulation Of Human Cytomegalovirus Replication By Micro-Rna 132 (Mir132), Micro-Rna 145 (Mir145) And Micro-Rna 212 (Mir212)
  • Methods And Compositions For The Treatment Of Eye Disorders With Increased Intraocular Pressure
  • Micromirs
  • Chiral Nucleic Acid Adjuvant Having Antitumor Effect And Antitumor Agent
  • Modulators Of Mir-323-3p For The Prevention Or Treatment Of Rheumatoid Arthritis
  • Polycomb-Associated Non-Coding Rnas
  • Anti-Angiogenic Mirna Therapeutics For Inhibiting Corneal Neovascularization
  • Antisense Rna For Treating Cancer And Inhibition Of Metastasis And Vectors For Antisense Sequestration
  • Microrna For Diagnostic And Therapeutic Purposes In Cardiovascular Diseases
  • Nucleic Acid Prodrugs And Methods Of Use Thereof
  • Crosslinked Micellar Spherical Nucleic Acids
  • Polyvalent Rna-Nanoparticle Compositions
  • Mir-103-2 For Diagnosing Poor Survival Prognosis Colon Adenocarcinoma.
  • Microrna (Mirna) And Downstream Targets For Diagnostic And Therapeutic Purposes
  • Cns Targeting Aav Vectors And Methods Of Use Thereof
  • Targeting Microrna-26a/B For The Treatment Of Neurodegenerative Disease
  • Modulation Of Mirna In Diseases With Aberrant Angiogenesis
  • Antidote Oligomers
  • Recombinant Aav Vectors Useful For Reducing Immunity Against Transgene Products
  • Therapeutic Targets And Molecules
  • Aav's And Uses Thereof
  • Control Of Whole Body Energy Homeostasis By Microrna Regulation
  • Pharmaceutical Compositions For Treatment Of Hcv Patients That Are Poor-Responders To Interferon
  • Polycomb-Associated Non-Coding Rnas
  • Asymmetric Auxiliary Group
  • Rna Interactome Of Polycomb Repressive Complex 1 (Prc1)
  • Isolation Of Novel Aav's And Uses Thereof
  • Methods Employing Non-Coding Rna Expression Assays
  • Inhibition Of Microrna-134 For The Treatment Of Seizure-Related Disorders And Neurologic Injuries
  • Multimeric Oligonucleotide Compounds
  • Aav-Based Treatment Of Cholesterol-Related Disorders
  • Compositions And Methods For Modulating Mecp2 Expression
  • Templated Nanoconjugates
  • Methods And Compositions For The Treatment Of Eye Disorders With Increased Intraocular Pressure
  • Particles For Detecting Intracellular Targets
  • Microrna Antisense Pnas, Compositions Comprising The Same, And Methods For Using And Evaluating The Same
  • Distinguishing Benign And Malignant Indeterminate Thyroid Lesions
  • Microrna Expression Profile Associated With Pancreatic Cancer
  • Sequence-Specific Inhibition Of Small Rna Function
  • Raav-Based Compositions And Methods For Treating Amyotrophic Lateral Sclerosis
  • Oligonucleotide Conjugates
  • Aav-Based Treatment Of Cholesterol-Related Disorders
  • Raav-Based Compositions And Methods
  • Mir-10a For Diagnosing Poor Survival Prognosis Colon Adenocarcinoma
  • Methods For The Synthesis Of Functionalized Nucleic Acids
  • Method For The Synthesis Of Phosphorus Atom Modified Nucleic Acids
  • Modulation Of T Cell Signaling Threshold And T Cell Sensitivity To Antigens
  • Recombinant Aav Variants And Uses Thereof
  • Compositions And Methods For Modifying A Predetermined Target Nucleic Acid Sequence
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Multimetric Oligonucleotide Compounds
  • Sequence-Specific Inhibition Of Small Rna Function
  • Modulation Of T Cell Signaling Threshold And T Cell Sensitivity To Antigens
  • Microrna Composition For The Treatment Of Neuroblastoma
  • Methods And Compositions For The Treatment Of Intestinal Conditions
  • Microrna-Based Methods And Compositions For Reprogramming Cells
  • Multicistronic Expression Constructs
  • Microrna Expression Profile Associated With Pancreatic Cancer
  • Gene Vector
  • Use Of Microrna-24 And/Or Its Targets For The Treatment And Prevention Of Ischemia And Induction Of Angiogenesis
  • Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding Rnas
  • Aav-Based Treatment Of Cholesterol-Related Disorders
  • Micro-Rna's That Regulate Muscle Cells
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nature04303

    DOI

    http://dx.doi.org/10.1038/nature04303

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1045870087

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/16258535


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biological Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biochemistry and Cell Biology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0604", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Genetics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "3' Untranslated Regions", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antagomirs", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cholesterol", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Computational Biology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Down-Regulation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gene Silencing", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "MicroRNAs", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oligonucleotides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "RNA, Complementary", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sensitivity and Specificity", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Substrate Specificity", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Up-Regulation", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Laboratory of Metabolic Diseases, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.134907.8", 
              "name": [
                "Laboratory of Metabolic Diseases, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kr\u00fctzfeldt", 
            "givenName": "Jan", 
            "id": "sg:person.01326501171.27", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326501171.27"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Biology and Mathematics, Center for Comparative Functional Genomics, Department of Biology, New York University, 10003, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.137628.9", 
              "name": [
                "Biology and Mathematics, Center for Comparative Functional Genomics, Department of Biology, New York University, 10003, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rajewsky", 
            "givenName": "Nikolaus", 
            "id": "sg:person.0604110653.10", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604110653.10"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/grid.417897.4", 
              "name": [
                "Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Braich", 
            "givenName": "Ravi", 
            "id": "sg:person.0651210271.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651210271.51"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/grid.417897.4", 
              "name": [
                "Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rajeev", 
            "givenName": "Kallanthottathil G.", 
            "id": "sg:person.01127665173.29", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127665173.29"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Howard Hughes Medical Institute, Laboratory of RNA Molecular Biology, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.134907.8", 
              "name": [
                "Howard Hughes Medical Institute, Laboratory of RNA Molecular Biology, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tuschl", 
            "givenName": "Thomas", 
            "id": "sg:person.010011672437.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010011672437.34"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/grid.417897.4", 
              "name": [
                "Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Manoharan", 
            "givenName": "Muthiah", 
            "id": "sg:person.0650611705.98", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650611705.98"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Laboratory of Metabolic Diseases, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.134907.8", 
              "name": [
                "Laboratory of Metabolic Diseases, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Stoffel", 
            "givenName": "Markus", 
            "id": "sg:person.01211623670.71", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211623670.71"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nature03076", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050225907", 
              "https://doi.org/10.1038/nature03076"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature02871", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043341870", 
              "https://doi.org/10.1038/nature02871"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature03702", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024825726", 
              "https://doi.org/10.1038/nature03702"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature03552", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020637207", 
              "https://doi.org/10.1038/nature03552"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrg1379", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001799892", 
              "https://doi.org/10.1038/nrg1379"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3302654", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022653137", 
              "https://doi.org/10.1038/sj.gt.3302654"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng1536", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037192337", 
              "https://doi.org/10.1038/ng1536"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature03315", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002085290", 
              "https://doi.org/10.1038/nature03315"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature03121", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043296399", 
              "https://doi.org/10.1038/nature03121"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature03817", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035771095", 
              "https://doi.org/10.1038/nature03817"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2005-10-30", 
        "datePublishedReg": "2005-10-30", 
        "description": "miRNAs acting naturallyThe discovery of microRNAs (miRNAs), the non-coding RNAs thought to be involved in many biological processes, is changing our perception of gene regulation. Little is known about their function in mammalian systems in vivo, but a newly developed group of compounds that silences miRNAs in mice should provide a powerful tool for the study of their function \u2014 and a potential therapeutic strategy for silencing miRNAs in disease. These \u2018antagomirs\u2019 are chemically engineered oligonucleotides with sequences that complement natural miRNAs. Intravenous administration of antagomirs to miR-16, -122, -192 and -194 in mice caused a marked reduction of corresponding miRNA expression in liver, lung, kidney, heart, muscle, intestine, fat, skin, bone marrow, ovaries and adrenals. In worms and flies, miRNAs play important developmental roles in the embryo. In vertebrates, various developmental genes have been shown to be targets of miRNA regulation, but there were no examples of miRNAs playing specific roles in known developmental processes. Now one such example has been found: miR-196 acts in mouse embryos as a mechanism to ensure accurate expression of genes primarily regulated by Hoxb8 and Shh transcription factors. This supports the idea that vertebrate miRNAs may function as a secondary level of gene regulation.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/nature04303", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1018957", 
            "issn": [
              "0028-0836", 
              "1476-4687"
            ], 
            "name": "Nature", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "7068", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "438"
          }
        ], 
        "keywords": [
          "gene regulation", 
          "non-coding RNA", 
          "examples of miRNAs", 
          "important developmental role", 
          "developmental genes", 
          "natural miRNAs", 
          "miRNA regulation", 
          "mammalian systems", 
          "transcription factors", 
          "developmental role", 
          "developmental processes", 
          "mouse embryos", 
          "biological processes", 
          "miRNAs", 
          "miRNA expression", 
          "potential therapeutic strategy", 
          "specific role", 
          "genes", 
          "microRNAs", 
          "regulation", 
          "embryos", 
          "miR-16", 
          "antagomir", 
          "expression", 
          "vertebrates", 
          "therapeutic strategies", 
          "vivo", 
          "powerful tool", 
          "bone marrow", 
          "HOXB8", 
          "RNA", 
          "flies", 
          "group of compounds", 
          "role", 
          "such example", 
          "sequence", 
          "mice", 
          "worms", 
          "oligonucleotide", 
          "function", 
          "discovery", 
          "marked reduction", 
          "ovaries", 
          "target", 
          "mechanism", 
          "marrow", 
          "intestine", 
          "muscle", 
          "process", 
          "levels", 
          "compounds", 
          "factors", 
          "liver", 
          "disease", 
          "acts", 
          "kidney", 
          "heart", 
          "strategies", 
          "tool", 
          "study", 
          "example", 
          "skin", 
          "reduction", 
          "adrenals", 
          "lung", 
          "accurate expression", 
          "fat", 
          "system", 
          "group", 
          "idea", 
          "administration", 
          "perception", 
          "secondary level", 
          "intravenous administration"
        ], 
        "name": "Silencing of microRNAs in vivo with \u2018antagomirs\u2019", 
        "pagination": "685-689", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1045870087"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nature04303"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "16258535"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nature04303", 
          "https://app.dimensions.ai/details/publication/pub.1045870087"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:51", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_396.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/nature04303"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nature04303'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nature04303'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nature04303'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nature04303'


     

    This table displays all metadata directly associated to this object as RDF triples.

    289 TRIPLES      21 PREDICATES      125 URIs      106 LITERALS      22 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nature04303 schema:about N1e63448dd99640f991103f915c8321ce
    2 N3d606b8faee04d95b30d3c0b79429ca4
    3 N4fe55f8ba6574df28a6f15682f5ec9b1
    4 N504d69e5cb79443c9ab9e4ab1a9d99a1
    5 N5e587927776f4aae89c9fc4c80388ce4
    6 N801949dc3dcf4854b279b2dd75a3d7c8
    7 N8a8b1893d9b0478c9cf0e327cc6a7678
    8 N8fe2ef2e49704784929361eba1ca0410
    9 N9e6d90adb6de49578c72a0fdb5e32ae1
    10 N9fa68a0d72ef45c39697e1585dff1727
    11 Naaaa0e98cd2448989e2ae3978222bdc7
    12 Nb5bad3a378e441bb9d44f805cd635095
    13 Ndff663b9f1df4de0b110b2f8fb2cc3fb
    14 Ne5e5f00550fa41b0b27ff2d5d2cd344d
    15 Nf3be394c38c14e61ad2e66909efd966d
    16 anzsrc-for:06
    17 anzsrc-for:0601
    18 anzsrc-for:0604
    19 schema:author N1e81b8060bc442b5bcc101f1aa3450bf
    20 schema:citation sg:pub.10.1038/nature02871
    21 sg:pub.10.1038/nature03076
    22 sg:pub.10.1038/nature03121
    23 sg:pub.10.1038/nature03315
    24 sg:pub.10.1038/nature03552
    25 sg:pub.10.1038/nature03702
    26 sg:pub.10.1038/nature03817
    27 sg:pub.10.1038/ng1536
    28 sg:pub.10.1038/nrg1379
    29 sg:pub.10.1038/sj.gt.3302654
    30 schema:datePublished 2005-10-30
    31 schema:datePublishedReg 2005-10-30
    32 schema:description miRNAs acting naturallyThe discovery of microRNAs (miRNAs), the non-coding RNAs thought to be involved in many biological processes, is changing our perception of gene regulation. Little is known about their function in mammalian systems in vivo, but a newly developed group of compounds that silences miRNAs in mice should provide a powerful tool for the study of their function — and a potential therapeutic strategy for silencing miRNAs in disease. These ‘antagomirs’ are chemically engineered oligonucleotides with sequences that complement natural miRNAs. Intravenous administration of antagomirs to miR-16, -122, -192 and -194 in mice caused a marked reduction of corresponding miRNA expression in liver, lung, kidney, heart, muscle, intestine, fat, skin, bone marrow, ovaries and adrenals. In worms and flies, miRNAs play important developmental roles in the embryo. In vertebrates, various developmental genes have been shown to be targets of miRNA regulation, but there were no examples of miRNAs playing specific roles in known developmental processes. Now one such example has been found: miR-196 acts in mouse embryos as a mechanism to ensure accurate expression of genes primarily regulated by Hoxb8 and Shh transcription factors. This supports the idea that vertebrate miRNAs may function as a secondary level of gene regulation.
    33 schema:genre article
    34 schema:isAccessibleForFree false
    35 schema:isPartOf N48371ea22d0e4fb4b55f2bad108c2266
    36 N7865f52b29514284b8e8fa0bad35eea0
    37 sg:journal.1018957
    38 schema:keywords HOXB8
    39 RNA
    40 accurate expression
    41 acts
    42 administration
    43 adrenals
    44 antagomir
    45 biological processes
    46 bone marrow
    47 compounds
    48 developmental genes
    49 developmental processes
    50 developmental role
    51 discovery
    52 disease
    53 embryos
    54 example
    55 examples of miRNAs
    56 expression
    57 factors
    58 fat
    59 flies
    60 function
    61 gene regulation
    62 genes
    63 group
    64 group of compounds
    65 heart
    66 idea
    67 important developmental role
    68 intestine
    69 intravenous administration
    70 kidney
    71 levels
    72 liver
    73 lung
    74 mammalian systems
    75 marked reduction
    76 marrow
    77 mechanism
    78 miR-16
    79 miRNA expression
    80 miRNA regulation
    81 miRNAs
    82 mice
    83 microRNAs
    84 mouse embryos
    85 muscle
    86 natural miRNAs
    87 non-coding RNA
    88 oligonucleotide
    89 ovaries
    90 perception
    91 potential therapeutic strategy
    92 powerful tool
    93 process
    94 reduction
    95 regulation
    96 role
    97 secondary level
    98 sequence
    99 skin
    100 specific role
    101 strategies
    102 study
    103 such example
    104 system
    105 target
    106 therapeutic strategies
    107 tool
    108 transcription factors
    109 vertebrates
    110 vivo
    111 worms
    112 schema:name Silencing of microRNAs in vivo with ‘antagomirs’
    113 schema:pagination 685-689
    114 schema:productId N992ad7763afe45688312c5059c43669f
    115 Na9f5b681d81f4f5c9fb8f0bf47a720a9
    116 Nee23c8687c9440cebf6fb3d9d26bf22c
    117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045870087
    118 https://doi.org/10.1038/nature04303
    119 schema:sdDatePublished 2022-09-02T15:51
    120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    121 schema:sdPublisher Nd9f2d71546e24d518931650e6bb49938
    122 schema:url https://doi.org/10.1038/nature04303
    123 sgo:license sg:explorer/license/
    124 sgo:sdDataset articles
    125 rdf:type schema:ScholarlyArticle
    126 N1e63448dd99640f991103f915c8321ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name Substrate Specificity
    128 rdf:type schema:DefinedTerm
    129 N1e81b8060bc442b5bcc101f1aa3450bf rdf:first sg:person.01326501171.27
    130 rdf:rest Nb96ee60ff0b945ab9056cc56355a5531
    131 N299a6a0e84ef480cad4f32dfb8800c8e rdf:first sg:person.010011672437.34
    132 rdf:rest N8fc182724a4b4ea0918511e4e9ac6e31
    133 N3d606b8faee04d95b30d3c0b79429ca4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Computational Biology
    135 rdf:type schema:DefinedTerm
    136 N461e9736abf8471aa6d9606cda76e82d rdf:first sg:person.01127665173.29
    137 rdf:rest N299a6a0e84ef480cad4f32dfb8800c8e
    138 N48371ea22d0e4fb4b55f2bad108c2266 schema:volumeNumber 438
    139 rdf:type schema:PublicationVolume
    140 N4fe55f8ba6574df28a6f15682f5ec9b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Time Factors
    142 rdf:type schema:DefinedTerm
    143 N504d69e5cb79443c9ab9e4ab1a9d99a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Antagomirs
    145 rdf:type schema:DefinedTerm
    146 N5e587927776f4aae89c9fc4c80388ce4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Gene Silencing
    148 rdf:type schema:DefinedTerm
    149 N7865f52b29514284b8e8fa0bad35eea0 schema:issueNumber 7068
    150 rdf:type schema:PublicationIssue
    151 N801949dc3dcf4854b279b2dd75a3d7c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    152 schema:name RNA, Complementary
    153 rdf:type schema:DefinedTerm
    154 N8a8b1893d9b0478c9cf0e327cc6a7678 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Cholesterol
    156 rdf:type schema:DefinedTerm
    157 N8fc182724a4b4ea0918511e4e9ac6e31 rdf:first sg:person.0650611705.98
    158 rdf:rest Nb8b48586cbf8462a945d356274144345
    159 N8fe2ef2e49704784929361eba1ca0410 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Down-Regulation
    161 rdf:type schema:DefinedTerm
    162 N992ad7763afe45688312c5059c43669f schema:name pubmed_id
    163 schema:value 16258535
    164 rdf:type schema:PropertyValue
    165 N9e6d90adb6de49578c72a0fdb5e32ae1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Up-Regulation
    167 rdf:type schema:DefinedTerm
    168 N9fa68a0d72ef45c39697e1585dff1727 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Oligonucleotides
    170 rdf:type schema:DefinedTerm
    171 Na9f5b681d81f4f5c9fb8f0bf47a720a9 schema:name doi
    172 schema:value 10.1038/nature04303
    173 rdf:type schema:PropertyValue
    174 Naaaa0e98cd2448989e2ae3978222bdc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Sensitivity and Specificity
    176 rdf:type schema:DefinedTerm
    177 Nb5bad3a378e441bb9d44f805cd635095 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name 3' Untranslated Regions
    179 rdf:type schema:DefinedTerm
    180 Nb60d2e6d7e6d44468e06e0e4067a8aef rdf:first sg:person.0651210271.51
    181 rdf:rest N461e9736abf8471aa6d9606cda76e82d
    182 Nb8b48586cbf8462a945d356274144345 rdf:first sg:person.01211623670.71
    183 rdf:rest rdf:nil
    184 Nb96ee60ff0b945ab9056cc56355a5531 rdf:first sg:person.0604110653.10
    185 rdf:rest Nb60d2e6d7e6d44468e06e0e4067a8aef
    186 Nd9f2d71546e24d518931650e6bb49938 schema:name Springer Nature - SN SciGraph project
    187 rdf:type schema:Organization
    188 Ndff663b9f1df4de0b110b2f8fb2cc3fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    189 schema:name MicroRNAs
    190 rdf:type schema:DefinedTerm
    191 Ne5e5f00550fa41b0b27ff2d5d2cd344d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    192 schema:name Mice
    193 rdf:type schema:DefinedTerm
    194 Nee23c8687c9440cebf6fb3d9d26bf22c schema:name dimensions_id
    195 schema:value pub.1045870087
    196 rdf:type schema:PropertyValue
    197 Nf3be394c38c14e61ad2e66909efd966d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    198 schema:name Animals
    199 rdf:type schema:DefinedTerm
    200 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
    201 schema:name Biological Sciences
    202 rdf:type schema:DefinedTerm
    203 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
    204 schema:name Biochemistry and Cell Biology
    205 rdf:type schema:DefinedTerm
    206 anzsrc-for:0604 schema:inDefinedTermSet anzsrc-for:
    207 schema:name Genetics
    208 rdf:type schema:DefinedTerm
    209 sg:journal.1018957 schema:issn 0028-0836
    210 1476-4687
    211 schema:name Nature
    212 schema:publisher Springer Nature
    213 rdf:type schema:Periodical
    214 sg:person.010011672437.34 schema:affiliation grid-institutes:grid.134907.8
    215 schema:familyName Tuschl
    216 schema:givenName Thomas
    217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010011672437.34
    218 rdf:type schema:Person
    219 sg:person.01127665173.29 schema:affiliation grid-institutes:grid.417897.4
    220 schema:familyName Rajeev
    221 schema:givenName Kallanthottathil G.
    222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127665173.29
    223 rdf:type schema:Person
    224 sg:person.01211623670.71 schema:affiliation grid-institutes:grid.134907.8
    225 schema:familyName Stoffel
    226 schema:givenName Markus
    227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211623670.71
    228 rdf:type schema:Person
    229 sg:person.01326501171.27 schema:affiliation grid-institutes:grid.134907.8
    230 schema:familyName Krützfeldt
    231 schema:givenName Jan
    232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326501171.27
    233 rdf:type schema:Person
    234 sg:person.0604110653.10 schema:affiliation grid-institutes:grid.137628.9
    235 schema:familyName Rajewsky
    236 schema:givenName Nikolaus
    237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604110653.10
    238 rdf:type schema:Person
    239 sg:person.0650611705.98 schema:affiliation grid-institutes:grid.417897.4
    240 schema:familyName Manoharan
    241 schema:givenName Muthiah
    242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650611705.98
    243 rdf:type schema:Person
    244 sg:person.0651210271.51 schema:affiliation grid-institutes:grid.417897.4
    245 schema:familyName Braich
    246 schema:givenName Ravi
    247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651210271.51
    248 rdf:type schema:Person
    249 sg:pub.10.1038/nature02871 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043341870
    250 https://doi.org/10.1038/nature02871
    251 rdf:type schema:CreativeWork
    252 sg:pub.10.1038/nature03076 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050225907
    253 https://doi.org/10.1038/nature03076
    254 rdf:type schema:CreativeWork
    255 sg:pub.10.1038/nature03121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043296399
    256 https://doi.org/10.1038/nature03121
    257 rdf:type schema:CreativeWork
    258 sg:pub.10.1038/nature03315 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002085290
    259 https://doi.org/10.1038/nature03315
    260 rdf:type schema:CreativeWork
    261 sg:pub.10.1038/nature03552 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020637207
    262 https://doi.org/10.1038/nature03552
    263 rdf:type schema:CreativeWork
    264 sg:pub.10.1038/nature03702 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024825726
    265 https://doi.org/10.1038/nature03702
    266 rdf:type schema:CreativeWork
    267 sg:pub.10.1038/nature03817 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035771095
    268 https://doi.org/10.1038/nature03817
    269 rdf:type schema:CreativeWork
    270 sg:pub.10.1038/ng1536 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037192337
    271 https://doi.org/10.1038/ng1536
    272 rdf:type schema:CreativeWork
    273 sg:pub.10.1038/nrg1379 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001799892
    274 https://doi.org/10.1038/nrg1379
    275 rdf:type schema:CreativeWork
    276 sg:pub.10.1038/sj.gt.3302654 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022653137
    277 https://doi.org/10.1038/sj.gt.3302654
    278 rdf:type schema:CreativeWork
    279 grid-institutes:grid.134907.8 schema:alternateName Howard Hughes Medical Institute, Laboratory of RNA Molecular Biology, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA
    280 Laboratory of Metabolic Diseases, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA
    281 schema:name Howard Hughes Medical Institute, Laboratory of RNA Molecular Biology, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA
    282 Laboratory of Metabolic Diseases, The Rockefeller University, 1230 York Avenue, 10021, New York, New York, USA
    283 rdf:type schema:Organization
    284 grid-institutes:grid.137628.9 schema:alternateName Biology and Mathematics, Center for Comparative Functional Genomics, Department of Biology, New York University, 10003, New York, New York, USA
    285 schema:name Biology and Mathematics, Center for Comparative Functional Genomics, Department of Biology, New York University, 10003, New York, New York, USA
    286 rdf:type schema:Organization
    287 grid-institutes:grid.417897.4 schema:alternateName Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA
    288 schema:name Alnylam Pharmaceuticals Inc., 300 3rd Street, 02142, Cambridge, Massachusetts, USA
    289 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...